RT Journal Article
T1 Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial.
A1 Perez, Antonio
A1 Carrasco-Sánchez, Francisco Javier
A1 González, Carlos
A1 Seguí-Ripoll, José Miguel
A1 Trescolí, Carlos
A1 Ena, Javier
A1 Borrell, Mireia
A1 Gomez Huelgas, Ricardo
K1 blood Glucose
K1 diabetes mellitus
K1 hypoglycemia
K1 insulin glargine
K1 type 2
AB This study assessed the efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in insufficiently controlled people with type 2 diabetes. COBALTA (for its acronym in Spanish, COntrol Basal durante la hospitalizacion y al ALTA) was a multicenter, open-label, single-arm, phase IV trial including 112 evaluable inpatients with type 2 diabetes insufficiently controlled (glycosylated hemoglobin (HbA1c) 8%-10%) with basal insulin and/or non-insulin antidiabetic drugs. Patients were treated with a basal-bolus-correction insulin regimen with Gla-300 during the hospitalization and with Gla-300 and/or non-insulin antidiabetics for 6 months after discharge. The primary endpoint was the HbA1c change from baseline to month 6 postdischarge. HbA1c levels decreased from 8.8%±0.6% at baseline to 7.2%±1.1% at month 6 postdischarge (p Inpatient and intensification therapy at discharge with Gla-300 improved significantly glycemic control of patients with type 2 diabetes insufficiently controlled with other basal insulin and/or non-insulin antidiabetic medication, with high treatment satisfaction. Gla-300 could therefore be a treatment choice for hospital and postdischarge diabetes management.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/16256
UL http://hdl.handle.net/10668/16256
LA en
DS RISalud
RD Apr 10, 2025